Locally Advanced Solid Tumor Clinical Trials

46 clinical trials for Locally Advanced Solid Tumor across international registries, including 16 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours — RECRUITING · PHASE1
• Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors — RECRUITING · PHASE3
• FOG-001 in Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors — RECRUITING · PHASE1
• 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors — RECRUITING · PHASE1
• A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) — RECRUITING · PHASE1
• Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors — RECRUITING · PHASE2
• Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors — RECRUITING · PHASE1
• A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) — RECRUITING · PHASE1
• Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors — RECRUITING · PHASE2
• CD8 PET Imaging in Metastatic Solid Tumours — RECRUITING · PHASE2
• A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer — RECRUITING · PHASE1
• A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) — RECRUITING · PHASE1
• ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) — RECRUITING · PHASE1
• IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) — RECRUITING
• A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab — ACTIVE_NOT_RECRUITING · PHASE1
• Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies — COMPLETED · PHASE1
• Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors — TERMINATED · PHASE1
• A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors — TERMINATED · PHASE1
• QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers — COMPLETED · PHASE1
• A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers — TERMINATED · PHASE1
• A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors — TERMINATED · PHASE2
• A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours — ACTIVE_NOT_RECRUITING · PHASE1
• A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors — TERMINATED · PHASE1
• Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors — COMPLETED · PHASE1
• Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation — ACTIVE_NOT_RECRUITING · PHASE1
• Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors — TERMINATED · PHASE2
• Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors — TERMINATED · PHASE1
• A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib — COMPLETED
• ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors — COMPLETED · PHASE1
• Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib — COMPLETED · PHASE1
• A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma — COMPLETED · PHASE1
• Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients — COMPLETED · PHASE1
• A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients — WITHDRAWN · PHASE1
• HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors — OTHER · PHASE1
• Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer — OTHER · PHASE2
• A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours — COMPLETED · PHASE1
• A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors — OTHER · PHASE1
• A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations — OTHER · PHASE1
• The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors — OTHER · PHASE1
• SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma — OTHER · PHASE2
• A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies — OTHER · PHASE1
• Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors — COMPLETED · PHASE1

Refine this search